02/02/2011

"http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&mv1=5&mv2=3&mh1=0&mh2=0&mh3=0&mh4=0&ms=0&any=2010&num=269" A global study of the Vall d'Hebron Universitary Hospital, led by the group of Gene Expression and Cancer at Vall d'Hebron Institute of Oncology, that identified cells which are the initiators of a brain tumor, glioma, and having the ability to regenerate after surgery, is one of 10 finalists for the new award "Vanguardia de la Ciencia', organized by the newspaper of Grupo Godó. Vall d'Hebron is a shared candidate with the team of Mariano Barbacid at CNIO, a breakthrough in lung cancer, both under the title "The research for new therapies against cancer".The results of the study, which focused specifically on the glioma, the most common malignant brain tumor, was published in Cancer Cell, signed by a 20 researchers from Vall d'Hebron, including the responsible for the cardiovascular diseases group at Vall d'Hebron Research Institute (VHIR), Dr. David Garcia-Dorado, or the responsible of the neurotrauma and neurosurgery group at VHIR, Dr. Juan Sahuquillo.The prize will be awarded after the opinion among readers of the newspaper, 50% of the final decision, and the scientific advisory committee, which also will decide at 50%. For supporting the candidacy of Vall d'Hebron, readers can vote at "http://www.lavanguardia.es/vanguardia-de-la-ciencia/index.html" www.lavanguardia.es/vanguardia-de-la-ciencia.